• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

Voxelotor can Promote Long-Term Benefits in Teens, Adults With SCD, Latest Clinical Data Show

Global Blood Therapeutics’ lead therapeutic candidate voxelotor can induce rapid, robust, and sustained improvements in the amount of hemoglobin in adolescents and adults with sickle cell disease (SCD), according to interim results from the first part of a Phase 3 trial.

The latest results of GBT’s clinical program for voxelotor were recently presented at the 60th American Society of Hematology Annual Meeting & Exposition in San Diego.

Findings from the ongoing Phase 3 HOPE trial (NCT03036813) were revealed in a presentation titled “Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031) at 24-weeks, a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease.”

The two-part study is designed to evaluate the effectiveness and safety of voxelotor in sickle cell patients ages 12 to 65.